 prevent stroke antihypertens drug treatment person isol systol hypertens final result systol hypertens elderli program shep shep cooper research group abil antihypertens drug treatment risk nonfat fatal total stroke isol systol hypertens multicent double-blind placebo-control community-bas ambulatori popul tertiari care center person screene year activ treatment systol blood pressur mm Hg diastol blood pressur mm Hg particip antihypertens medic initi contact averag systol blood pressur mm Hg averag diastol blood pressur mm Hg mean age year women black particip clinic center antihypertens medic statu initi contact step trial chlorthalidon mg/d placebo mg/d step atenolol mg/d placebo mg/d main outcom nonfat fatal total stroke cardiovascular coronari morbid mortal all-caus mortal qualiti life measur averag follow-up year averag systol blood pressur mm Hg placebo group mm Hg activ treatment group averag diastol blood pressur mm Hg incid total stroke particip activ treatment placebo rel risk proport hazard regress analysi secondari end point clinic nonfat myocardi infarct coronari death rel risk major cardiovascular event rel risk death caus rel risk person year isol systol hypertens antihypertens stepped-car drug treatment low-dos chlorthalidon step medic incid total stroke absolut benefit event particip major cardiovascular event absolut benefit event